Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT06765317
Recruiting
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Phase 2 · United States · 8 sites
Registry update: 30 Oct 2026
NCT06758037
Recruiting
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
Phase 2 · China · 1 site
Registry update: 18 Mar 2025
NCT06760039
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Phase 1/2 · China · 10 sites
Registry update: 3 Apr 2025
NCT06792253
Recruiting
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3 · China · 1 site
Registry update: 19 Aug 2026
NCT06208735
Recruiting
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · Canada · 7 sites
Registry update: 14 Oct 2026
2024-511151-18-01
Recruiting
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
Phase 1 · Netherlands · 1 site
Registry update: 25 Nov 2024
NCT06779435
Recruiting
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Not applicable · China · 1 site
Registry update: 19 Feb 2025
NCT06693830
Recruiting
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Not applicable · United States · 1 site
Registry update: 23 Jan 2026
NCT06736613
Recruiting
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · United States · 7 sites
Registry update: 18 Dec 2025
NCT06701357
Recruiting
CR-CHOP+X in Previously Untreated DEL
Phase 2 · China · 1 site
Registry update: 30 Dec 2024
2024-512835-53-00
Recruiting
LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
Phase 2 · Spain · 15 sites
Registry update: 27 Sept 2024
NCT06683885
Recruiting
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1/2 · China · 1 site
Registry update: 12 Nov 2024
NCT07254754
Recruiting
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Phase 2 · Spain · 15 sites
Registry update: 28 Nov 2025
NCT06742502
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Phase 2 · China · 2 sites
Registry update: 5 Jun 2025
NCT06682130
Recruiting
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Phase 2 · China · 1 site
Registry update: 14 Jul 2025
NCT07072208
Recruiting
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
Not applicable · China · 1 site
Registry update: 18 Jul 2025
NCT06544265
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · United States · 5 sites
Registry update: 14 Apr 2026
NCT06647940
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Phase 2 · China · 11 sites
Registry update: 22 Oct 2024
NCT06651853
Recruiting
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Phase 2 · China · 1 site
Registry update: 23 Jul 2025
NCT06458439
Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Phase 2 · United States · 1 site
Registry update: 27 May 2026

Ordered by registry start date. Freshness and sponsorship never change the order.